Top Banner
<br /> A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented By William Tap at 2014 ASCO Annual Meeting
23

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Dec 16, 2015

Download

Documents

Abbigail Ker
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

<br /> A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS)

Presented By William Tap at 2014 ASCO Annual Meeting

Page 2: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Pigmented Villonodular Synovitis (PVNS)<br />Tenosynovial Giant Cell Tumor (TGCT)

Presented By William Tap at 2014 ASCO Annual Meeting

Page 3: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Pigmented Villonodular Synovitis (PVNS)

Presented By William Tap at 2014 ASCO Annual Meeting

Page 4: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 4

Presented By William Tap at 2014 ASCO Annual Meeting

Page 5: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Can we help patients (PVNS) <br />with a highly targeted therapy (PLX3397)<br />that blocks the CSF1R pathway <br />in this clonal neoplastic process frequently<br />initiated by a single genetic event?

Presented By William Tap at 2014 ASCO Annual Meeting

Page 6: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Study Goals

Presented By William Tap at 2014 ASCO Annual Meeting

Page 7: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Study Design

Presented By William Tap at 2014 ASCO Annual Meeting

Page 8: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Efficacy Assessments

Presented By William Tap at 2014 ASCO Annual Meeting

Page 9: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Tumor Volume Score (TVS)

Presented By William Tap at 2014 ASCO Annual Meeting

Page 10: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Patient Disposition

Presented By William Tap at 2014 ASCO Annual Meeting

Page 11: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Patient Characteristics: Safety Population (n=23)

Presented By William Tap at 2014 ASCO Annual Meeting

Page 12: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Safety: PVNS Expansion Cohort AEs<br />n = 23 Safety Population

Presented By William Tap at 2014 ASCO Annual Meeting

Page 13: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Treatment-Related AEs ≥ Grade 3

Presented By William Tap at 2014 ASCO Annual Meeting

Page 14: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Duration of Treatment (DOT), April 2014 data cutoff:<br />Median 256 days (range 21-585 days)

Presented By William Tap at 2014 ASCO Annual Meeting

Page 15: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

14 patients evaluable with TVS

Presented By William Tap at 2014 ASCO Annual Meeting

Page 16: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 16

Presented By William Tap at 2014 ASCO Annual Meeting

Page 17: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 17

Presented By William Tap at 2014 ASCO Annual Meeting

Page 18: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 18

Presented By William Tap at 2014 ASCO Annual Meeting

Page 19: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 19

Presented By William Tap at 2014 ASCO Annual Meeting

Page 20: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 20

Presented By William Tap at 2014 ASCO Annual Meeting

Page 21: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Slide 21

Presented By William Tap at 2014 ASCO Annual Meeting

Page 22: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Conclusions

Presented By William Tap at 2014 ASCO Annual Meeting

Page 23: A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

Thank You

Presented By William Tap at 2014 ASCO Annual Meeting